SYRE vs. NVDA

Last updated Jun 25, 2026

SYRE (Spyre Therapeutics Inc.) and NVDA (NVIDIA Corporation) are both stocks. SYRE operates in Biotechnology (Healthcare), while NVDA operates in Semiconductors (Technology). Over the past 10 years, SYRE returned -4.31%/yr vs 67.85%/yr for NVDA. At a 0.19 correlation, their price movements are largely independent.

Performance

SYRE vs. NVDA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Spyre Therapeutics Inc. (SYRE) and NVIDIA Corporation (NVDA). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, SYRE achieves a 163.25% return, which is significantly higher than NVDA's 6.83% return. Over the past 10 years, SYRE has underperformed NVDA with an annualized return of -4.31%, while NVDA has yielded a comparatively higher 67.85% annualized return.

SYRE

• 1D: -11.14%
• 1M: 16.46%
• YTD: 163.25%
• 6M: 160.94%
• 1Y: 459.64%
• 3Y*: 105.07%
• 5Y*: -15.12%
• 10Y*: -4.31%

NVDA

• 1D: -0.52%
• 1M: -7.48%
• YTD: 6.83%
• 6M: 5.64%
• 1Y: 34.73%
• 3Y*: 67.79%
• 5Y*: 60.02%
• 10Y*: 67.85%

*Multi-year figures are annualized to reflect compound growth (CAGR)

SYRE vs. NVDA - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
SYRE Spyre Therapeutics Inc.	163.25%	40.72%	8.18%	91.33%	-90.53%	-39.64%	3.01%	2.00%	38.45%	24.37%
NVDA NVIDIA Corporation	6.83%	38.92%	171.25%	239.02%	-50.26%	125.48%	122.30%	76.94%	-30.82%	81.99%

Correlation

The correlation between SYRE and NVDA is 0.15, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.15
Correlation (3Y) Calculated over the trailing 3-year period	0.19
Correlation (5Y) Calculated over the trailing 5-year period	0.18
Correlation (10Y) Calculated over the trailing 10-year period	0.19
Correlation (All Time) Calculated using the full available price history since Apr 7, 2016	0.19

Fundamentals

Market Cap SYRE : $29.84B NVDA : $4.85T
EPS SYRE : -$0.88 NVDA : $6.53
PS Ratio SYRE : 193.74 NVDA : 19.20
PB Ratio SYRE : 56.91 NVDA : 24.83
Total Revenue (TTM) SYRE : $90.49M NVDA : $253.49B
Gross Profit (TTM) SYRE : $0.00 NVDA : $187.95B
EBITDA (TTM) SYRE : -$171.29M NVDA : $192.76B

Return for Risk

SYRE vs. NVDA — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

SYRE

SYRE Risk / Return Rank: 99
SYRE Sharpe Ratio Rank: 99
SYRE Sortino Ratio Rank: 99
SYRE Omega Ratio Rank: 97
SYRE Calmar Ratio Rank: 100
SYRE Martin Ratio Rank: 100

NVDA

NVDA Risk / Return Rank: 70
NVDA Sharpe Ratio Rank: 73
NVDA Sortino Ratio Rank: 67
NVDA Omega Ratio Rank: 65
NVDA Calmar Ratio Rank: 73
NVDA Martin Ratio Rank: 73

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

SYRE vs. NVDA - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Spyre Therapeutics Inc. (SYRE) and NVIDIA Corporation (NVDA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.

	SYRE	NVDA	Difference
Sharpe ratio: Return per unit of total volatility	6.65	0.99	+5.67
Sortino ratio: Return per unit of downside risk	5.48	1.52	+3.96
Omega ratio: Gain probability vs. loss probability	1.65	1.18	+0.47
Calmar ratio: Return relative to maximum drawdown	27.61	1.73	+25.88
Martin ratio: Return relative to average drawdown	76.54	3.99	+72.55

SYRE vs. NVDA - Sharpe Ratio Comparison

The current SYRE Sharpe Ratio is 6.65, which is higher than the NVDA Sharpe Ratio of 0.99. The chart below compares the historical Sharpe Ratios of SYRE and NVDA, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Drawdowns

SYRE vs. NVDA - Drawdown Comparison

The maximum SYRE drawdown since its inception was -99.11%, which is greater than NVDA's maximum drawdown of -89.72%. Use the drawdown chart below to compare losses from any high point for SYRE and NVDA.

Drawdown Indicators

	SYRE	NVDA	Difference
Max Drawdown Largest peak-to-trough decline	-99.11%	-89.72%	-9.39%
Max Drawdown (1Y) Largest decline over 1 year	-16.79%	-20.21%	+3.42%
Max Drawdown (3Y) Largest decline over 3 years	-73.99%	-36.88%	-37.11%
Max Drawdown (5Y) Largest decline over 5 years	-98.74%	-66.34%	-32.40%
Max Drawdown (10Y) Largest decline over 10 years	-99.04%	-66.34%	-32.70%
Current Drawdown Current decline from peak	-71.23%	-15.49%	-55.74%
Average Drawdown Average peak-to-trough decline	-62.69%	-36.15%	-26.54%
Ulcer Index Depth and duration of drawdowns from previous peaks	6.04%	8.72%	-2.68%

Volatility

SYRE vs. NVDA - Volatility Comparison

Spyre Therapeutics Inc. (SYRE) has a higher volatility of 24.72% compared to NVIDIA Corporation (NVDA) at 13.20%. This indicates that SYRE's price experiences larger fluctuations and is considered to be riskier than NVDA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	SYRE	NVDA	Difference
Volatility (1M) Calculated over the trailing 1-month period	24.72%	13.20%	+11.52%
Volatility (6M) Calculated over the trailing 6-month period	49.19%	26.66%	+22.53%
Volatility (1Y) Calculated over the trailing 1-year period	69.78%	35.50%	+34.28%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	179.32%	51.84%	+127.48%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	136.24%	49.86%	+86.38%

Dividends

SYRE vs. NVDA - Dividend Comparison

SYRE has not paid dividends to shareholders, while NVDA's dividend yield for the trailing twelve months is around 0.14%.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
NVDA NVIDIA Corporation	0.14%	0.02%	0.03%	0.03%	0.11%	0.05%	0.12%	0.27%	0.46%	0.29%	0.45%	1.20%
SYRE Spyre Therapeutics Inc.	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Financials

Frequently Asked Questions

Can I hold both SYRE and NVDA in my portfolio?

SYRE and NVDA have a correlation of 0.15, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, SYRE or NVDA?

SYRE has higher volatility (24.72%) compared to NVDA (13.20%). In terms of maximum drawdown, SYRE dropped -99.11% vs NVDA's -89.72%.

Which has better risk-adjusted returns?

SYRE currently has the higher Sharpe Ratio (6.65 vs 0.99), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.